EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Frovatriptan for the acute treatment of migraine and prevention of predictable menstrual migraine



Frovatriptan for the acute treatment of migraine and prevention of predictable menstrual migraine



Expert Review of Neurotherapeutics 8(5): 723-736



Frovatriptan is a 5-HT(1B/1D) receptor agonist that belongs to the triptan therapeutic class. Relative to other triptans, frovatriptan has a long half-life (26 h) and a low incidence of migraine recurrence (17%). Frovatriptan is indicated for the acute treatment of migraine with or without aura, and has a relatively good safety and tolerability profile. Recent studies have also shown that a 6-day regimen of frovatriptan scheduled during the perimenstrual period significantly reduced the incidence and severity of menstrual migraine (MM; attacks that regularly start day -2 to +3 relative to menses). Prevention may be important because MM attacks have been characterized as being of longer duration, more severe and more refractory to treatment than non-MM attacks.

(PDF emailed within 0-6 h: $19.90)

Accession: 053315352

Download citation: RISBibTeXText

PMID: 18457529

DOI: 10.1586/14737175.8.5.723



Related references

Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: Results of a new analysis of data from five previously published studies. Gender Medicine 7(2): 88-108, 2010

A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 63(2): 261-269, 2004

A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 64(5): 931.1-931, 2005

Pharmacokinetics of Two 6-Day Frovatriptan Dosing Regimens Used for the Short-Term Prevention of Menstrual Migraine. Clinical Drug Investigation 29(5): 325-337, 2009

Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia 29(11): 1133-1148, 2009

Efficacy of menstrually associated migraine prophylaxis with frovatriptan in true menstrual migraine patients and in patients with menstrually related migraine. Cephalalgia 23(7): 696, September, 2003

A review of frovatriptan for the treatment of menstrual migraine. International Journal of Women's Health 6: 523-535, 2014

Efficacy of early vs. late use of frovatriptan combined with dexketoprofen vs. frovatriptan alone in the acute treatment of migraine attacks with or without aura. Neurological Sciences 35 Suppl 1: 107-113, 2015

Efficacy of frovatriptan versus other triptans in the acute treatment of menstrual migraine: pooled analysis of three double-blind, randomized, crossover, multicenter studies. Neurological Sciences 33 Suppl 1: S65-S69, 2013

Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study. Journal of Headache and Pain 13(5): 401-406, 2012

Frovatriptan vs. other triptans for the acute treatment of oral contraceptive-induced menstrual migraine: pooled analysis of three double-blind, randomized, crossover, multicenter studies. Neurological Sciences 34 Suppl 1: S83-S86, 2014

Frovatriptan: a review of pharmacology, pharmacokinetics and clinical potential in the treatment of menstrual migraine. Therapeutics and Clinical Risk Management 2(3): 303-308, 2008

The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study Group. Obstetrics and Gynecology 86(6): 911-916, 1995

Early (≤ 1-h) vs. late (>1-h) administration of frovatriptan plus dexketoprofen combination vs. frovatriptan monotherapy in the acute treatment of migraine attacks with or without aura: a post hoc analysis of a double-blind, randomized, parallel group study. Neurological Sciences 36 Suppl 1: 161-167, 2016

Frovatriptan. For treatment of acute migraine. Revue de L'infirmiere: 47-49, 2010